Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
Number 4: In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in the biosimilars landscape, coinciding with ongoing legal disputes ...
A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% ...
Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex ...
The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...
A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...
A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment ...
In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...
On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...
Ivo Abraham, PhD, RN, University of Arizona Cancer Center, explains how biosimilars are becoming more accessible but face ...
The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...
Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback